Krajsova, I: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

1

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion-Sileni, Vanna, Dutriaux,

Journal:

The Lancet Oncology

Year:

2018

Language:

english

File:

PDF, 371 KB

english, 2018

2

1373TiPILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

Butler, M O, Robert, C, Negrier, S, In, G K, Walker, J, Krajsova, I, Atkinson, V G, Hansson, J, Kapiteijn, E, Loquai, C, Shaw, H M, Cheng, T, Mansard, S, Grob, J J, Guidoboni, M, Mehta, M, Ascierto, P

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 96 KB

2019

3

1215OResults of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma

Dummer, R., Ascierto, P.A., Gogas, H., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., L

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 67 KB

english, 2017

4

Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroyakovskiy, D., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsová, I., Hauschild, A., Mookerj

Journal:

Annals of Oncology

Year:

2016

Language:

english

File:

PDF, 45 KB

english, 2016

5

KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients

Janku, Filip, Novotny, Jan, Julis, Ivan, Julisova, Ivana, Pecen, Ladislav, Tomancova, Vera, Kocmanova, Gabriela, Krasna, Luboslava, Krajsova, Ivana, Stork, Jiri, Petruzelka, Lubos

Journal:

Melanoma Research

Year:

2005

Language:

english

File:

PDF, 227 KB

english, 2005

6

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma

Ascierto, Paolo A., Dummer, Reinhard, Gogas, Helen J., Flaherty, Keith T., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, de Groot, J

Journal:

European Journal of Cancer

Year:

2020

File:

PDF, 1.84 MB

2020

7

Données de survie globale de l’étude COLUMBUS, étude de phase III avec encorafénib (ENCO) plus binimétinib (BINI) versus vémurafénib (VEM) ou encorafénib (ENCO) dans le mélanome métastatique BRAF muté

Robert, C., Dummer, R., Ascierto, P.A., Gogas, H.J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Y

Journal:

Annales de Dermatologie et de Vénéréologie

Year:

2018

File:

PDF, 234 KB

2018

8

1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS

Robert, C., Flaherty, K.T., Gogas, H.J., Fernandez, A.M. Arance, Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., de Groot, J.W.B., Dutriaux, C., Loquai, C., Harney, A.

Journal:

Annals of Oncology

Year:

2020

File:

PDF, 109 KB

2020

9

P39 Giant nodular polypoid melanoma of the neck

Plzakova, Z., Krajsova, I., Sukova, T., Prochazkova, I.

Journal:

Melanoma Research

Year:

2010

Language:

english

File:

PDF, 54 KB

english, 2010

10

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsova, I., Hausc

Journal:

European Journal of Cancer

Year:

2015

Language:

english

File:

PDF, 60 KB

english, 2015

11

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

Blank, Christian U., Larkin, James, Arance, Ana M., Hauschild, Axel, Queirolo, Paola, Del Vecchio, Michele, Ascierto, Paolo A., Krajsova, Ivana, Schachter, Jacob, Neyns, Bart, Garbe, Claus, Chiarion S

Journal:

European Journal of Cancer

Year:

2017

Language:

english

File:

PDF, 464 KB

english, 2017

12

1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

Arance, A., Dummer, R., Ascierto, P.A., Gogas, H., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., L

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 50 KB

english, 2017

13

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Gogas, Helen J., Flaherty, Keith T., Dummer, Reinhard, Ascierto, Paolo A., Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Sileni, Van

Journal:

European Journal of Cancer

Year:

2019

Language:

english

File:

PDF, 694 KB

english, 2019

14

1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma

Gogas, H., Dummer, R., Ascierto, P.A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., L

Journal:

Annals of Oncology

Year:

2017

Language:

english

File:

PDF, 53 KB

english, 2017

15

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Dummer, Reinhard, Ascierto, Paolo A, Gogas, Helen J, Arance, Ana, Mandala, Mario, Liszkay, Gabriella, Garbe, Claus, Schadendorf, Dirk, Krajsova, Ivana, Gutzmer, Ralf, Chiarion Sileni, Vanna, Dutriaux,

Journal:

The Lancet Oncology

Year:

2018

Language:

english

File:

PDF, 733 KB

english, 2018

16

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, James, Brown, Michael P., Arance, Ana M., Hauschild, Axel, Queirolo, Paola, Vecchio, Michele Del, Ascierto, Paolo A., Krajsová, Ivana, Schachter, Jacob, Neyns, Bart, Garbe, Claus, Sileni, Vann

Journal:

European Journal of Cancer

Year:

2019

Language:

english

File:

PDF, 1.24 MB

english, 2019

17

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

Larkin, James, Del Vecchio, Michele, Ascierto, Paolo A, Krajsova, Ivana, Schachter, Jacob, Neyns, Bart, Espinosa, Enrique, Garbe, Claus, Sileni, Vanna Chiarion, Gogas, Helen, Miller, Wilson H, Mandalà

Journal:

The Lancet Oncology

Year:

2014

Language:

english

File:

PDF, 297 KB

english, 2014

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Z-Library Since 2009 support@1delivery.pm

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски